Related Experiment Video

Updated: Apr 26, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

3.0K

Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer

Rena Callahan1

  • 1UCLA Medical Center, Hematology Oncology, Los Angeles, California.

Journal of the Advanced Practitioner in Oncology
|July 18, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.3K

Related Experiment Videos

Last Updated: Apr 26, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

3.0K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

7.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

Articles linked to this work by shared authors, journal, and citation graph.

Novel Endocrine Therapies: Current Status and Future Directions.

Clinical breast cancer·2026

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer.

Breast cancer research and treatment·2026

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09).

Therapeutic advances in medical oncology·2018

Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.

Current opinion in obstetrics & gynecology·2011

Fixed Treatment Duration Mosunetuzumab in Patients With Relapsed or Refractory Follicular Lymphoma: Perspectives From US Advanced Practice Providers.

Journal of the advanced practitioner in oncology·2026

Assessment of Advanced Practitioner Oncogenomic Training and Proficiency Before and After the Intervention of an Oncogenomic Module.

Journal of the advanced practitioner in oncology·2026

Concurrent Ocular and Dermatologic Toxicities Associated With Docetaxel Chemotherapy.

Journal of the advanced practitioner in oncology·2026

Optimizing Polycythemia Vera Management Through a Collaborative Care Model Between Leukemia Oncologists and an Integrated Specialty Pharmacy.

Journal of the advanced practitioner in oncology·2026

Capecitabine-Induced Hand-Foot Syndrome With Genital Involvement.

Journal of the advanced practitioner in oncology·2026

Next in Line: Building a Succession Pipeline for Advanced Practitioners in Oncology.

Journal of the advanced practitioner in oncology·2026

Ubiquitin signaling in tumor-associated macrophage reprogramming: mechanisms and therapeutic opportunities in cancers.

Biomarker research·2026

In primary human lymphocytes, the triazole fungicide cyproconazole impairs regulatory B cell interleukin-10 expression and induces T cell senescence.

Environmental toxicology and pharmacology·2026

Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer.

Cell reports. Medicine·2026

CTLA4 rs3087243-A-linked haplotype is associated with increased CTLA-4 expression and suppressive function in human regulatory T cells.

Journal of immunology (Baltimore, Md. : 1950)·2026

pH-responsive biomimetic liposomes enhance targeted immunotherapy of bladder cancer.

Science China. Life sciences·2026

[Features of local and systemic production of major immune response cytokines in epithelial lacrimal gland tumors].

Vestnik oftalmologii·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us